Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RH 1

Drug Profile

RH 1

Alternative Names: RH-1

Latest Information Update: 10 Sep 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Research Technology; University of Colorado at Denver; University of Salford
  • Developer Allos Therapeutics
  • Class Antineoplastics; Aziridines; Benzoquinones; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 06 Sep 2012 Allos Therapeutics has been acquired by Spectrum Pharmaceuticals
  • 09 Mar 2009 Rh 1 is available for licensing outside the US (http://www.allos.com)
  • 14 Nov 2007 Phase-I clinical trials in Non-Hodgkin's lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top